Profile data is unavailable for this security.
About the company
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
- Revenue in USD (TTM)718.95m
- Net income in USD-38.55m
- Incorporated2005
- Employees674.00
- LocationSupernus Pharmaceuticals Inc9715 Key West AvenueROCKVILLE 20850United StatesUSA
- Phone+1 (301) 838-2500
- Fax+1 (302) 636-5454
- Websitehttps://www.supernus.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix Inc | 51.95m | -265.94m | 2.34bn | 325.00 | -- | 3.55 | -- | 45.09 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Apellis Pharmaceuticals Inc | 1.00bn | 22.39m | 2.58bn | 733.00 | 163.27 | 6.90 | 107.62 | 2.57 | 0.1235 | 0.1235 | 7.90 | 2.92 | 1.02 | 0.913 | 3.18 | 1,369,416.00 | 2.28 | -48.52 | 3.09 | -62.30 | 89.81 | 87.55 | 2.23 | -90.49 | 2.70 | 1.78 | 0.5516 | -- | 28.46 | 31.98 | 111.31 | -- | -43.47 | -- |
| Liquidia Corp | 69.22m | -121.85m | 2.76bn | 157.00 | -- | 125.12 | -- | 39.94 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 2.86bn | 979.00 | -- | 6.27 | -- | 7.30 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Catalyst Pharmaceuticals Inc | 588.99m | 214.33m | 2.92bn | 182.00 | 14.20 | 3.07 | 11.58 | 4.96 | 1.68 | 1.68 | 4.63 | 7.79 | 0.6024 | 3.08 | 6.14 | 3,236,203.00 | 21.92 | 22.15 | 25.40 | 25.81 | 85.19 | 85.59 | 36.39 | 31.20 | 5.82 | -- | 0.00 | 0.00 | 19.78 | 37.68 | 30.78 | 23.37 | 38.45 | -- |
| Arcutis Biotherapeutics Inc | 376.07m | -16.14m | 2.93bn | 354.00 | -- | 15.36 | -- | 7.78 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Supernus Pharmaceuticals Inc | 718.95m | -38.55m | 3.14bn | 674.00 | -- | 2.95 | 59.14 | 4.37 | -0.6839 | -0.6839 | 12.70 | 18.48 | 0.5098 | 1.09 | 4.36 | -- | -2.73 | 2.01 | -3.52 | 2.67 | 89.63 | 87.96 | -5.36 | 4.66 | 1.66 | -- | -- | -- | 8.63 | 6.68 | -152.19 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 451.36m | -66.42m | 3.26bn | 370.00 | -- | 9.49 | -- | 7.22 | -1.61 | -1.61 | 10.81 | 8.07 | 0.9612 | 8.78 | 6.85 | 1,219,892.00 | -14.14 | -27.80 | -18.38 | -32.78 | 93.20 | 93.45 | -14.72 | -53.60 | 3.82 | -- | 0.1742 | -- | 146.71 | -- | 42.52 | -- | 84.92 | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.26bn | 600.00 | 18.25 | 1.78 | 15.07 | 2.96 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 677.56m | 59.01m | 3.47bn | 366.00 | 60.92 | 6.10 | 57.34 | 5.12 | 0.7448 | 0.7448 | 8.58 | 7.44 | 1.01 | 1.91 | 23.64 | 1,851,268.00 | 8.78 | 2.35 | 10.69 | 2.75 | 88.54 | 87.48 | 8.71 | 3.40 | 3.39 | -- | 0.00 | 0.00 | 60.09 | -- | 236.61 | -- | 40.84 | -- |
| Corcept Therapeutics Inc | 761.41m | 99.65m | 3.75bn | 730.00 | 42.49 | 5.77 | 37.23 | 4.93 | 0.8303 | 0.8303 | 6.35 | 6.11 | 0.908 | 1.03 | 13.39 | 1,043,023.00 | 11.88 | 17.68 | 14.54 | 20.76 | 98.30 | 98.47 | 13.09 | 20.88 | 2.85 | -- | 0.00 | 0.00 | 12.79 | 16.56 | -29.43 | -1.23 | -29.80 | -- |
| Indivior Pharmaceuticals, Inc | 1.18bn | 122.00m | 3.86bn | 1.03k | 32.18 | -- | 26.09 | 3.27 | 0.9592 | 0.9592 | 9.20 | -1.66 | 0.8194 | 1.03 | 4.63 | 1,145,631.00 | 8.68 | -1.36 | 26.23 | -2.98 | 85.51 | 84.87 | 10.59 | -2.47 | 0.7938 | 9.33 | 2.80 | -- | 8.69 | 8.64 | 101.55 | -56.87 | 34.66 | -- |
| ADMA Biologics Inc | 510.17m | 146.93m | 3.90bn | 647.00 | 27.32 | 8.16 | 25.16 | 7.65 | 0.5996 | 0.5996 | 2.08 | 2.01 | 0.9168 | 1.15 | 4.90 | 788,520.90 | 26.40 | 9.62 | 29.75 | 10.91 | 57.39 | 44.75 | 28.80 | 12.51 | 3.74 | 37.09 | 0.1313 | 0.00 | 19.63 | 64.60 | -25.67 | -- | 12.46 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 4.07bn | 68.00 | 98.29 | 4.23 | 49.19 | 16.21 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
Data as of Mar 04 2026. Currency figures normalised to Supernus Pharmaceuticals Inc's reporting currency: US Dollar USD
57.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 7.82m | 13.95% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.60m | 9.98% |
| Millennium Management LLCas of 11 Feb 2026 | 3.28m | 5.85% |
| Armistice Capital LLCas of 31 Dec 2025 | 2.76m | 4.93% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.59m | 4.61% |
| Nomura Investment Management Business Trustas of 31 Dec 2025 | 2.31m | 4.12% |
| Point72 Asset Management LPas of 31 Dec 2025 | 2.26m | 4.04% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.22m | 3.96% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 1.73m | 3.09% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.47m | 2.63% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
